Pulse Biosciences to Present New Data on Nano-Pulse Stimulation Procedure for Sebaceous Hyperplasia and for Focal Epithelial Hyperplasia at 2022 American Society of Laser Medicine and Surgery Annual Conference
April 26 2022 - 8:00AM
Business Wire
Oral podium presentation highlights new long-term clinical
results to clear Sebaceous Hyperplasia (SH) with high efficacy,
continued improvement and good cosmesis
Poster presents successful first case report of NPS procedure
for recalcitrant HPV-related dermatosis on the lips
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric
medicine company commercializing the CellFX® System powered by
Nano-Pulse Stimulation™ (NPS™) technology, today announced that one
oral presentation and one poster presentation on the results of
performing the CellFX procedure for lesion clearance will be
delivered at the 2022 American Society for Laser Medicine and
Surgery (ASLMS) Annual Meeting, taking place on April 27-30, 2022
in San Diego, California.
In a study for the treatment of Sebaceous Hyperplasia (SH),
12-month data demonstrated durable efficacy for the clearance of
Sebaceous Hyperplasia lesions. Investigators reported that 73% of
lesions had maintained or improved clearance, with good
cosmesis.
“It is impressive to see the long-term response of lesion
clearance achieved in this study of NPS technology for Sebaceous
Hyperplasia,” said Girish Munavalli, MD, medical director and
founder of Dermatology, Laser & Vein Specialists of the
Carolinas, Charlotte, NC and study investigator. “These results
demonstrate a high degree of efficacy and durable results that
clearly sets this cellular-specific procedure apart from other
treatment options used to remove lesions.”
The poster abstract on Nano-Pulse Stimulation technology
showcases a case report that generated positive results of clearing
refractory focal epithelial hyperplasia (FEH) on the lips with the
NPS procedure. In this case, the patient had failed previous
treatments, including topical creams such as imiquimod and
tretinoin, candida injections and liquid nitrogen therapy. FEH is a
disfiguring skin condition that presents as multiple discrete
papules on the lips and is caused by a specific human papilloma
virus (HPV) infection in the mouth that can be difficult to treat
and is prone to recurrence.
“We are delighted to participate in the ASLMS meeting this year
where dermatology thought leaders continue to demonstrate the
clinical efficacy and safety of the CellFX procedure to clear
challenging benign lesions,” said Kevin Danahy, Chief Commercial
Officer of Pulse Biosciences. “As we strive to help patients regain
confidence in the appearance of their skin by removing unwanted
benign lesions, we look forward to connecting with ASLMS members to
discuss the high clinical and commercial value of our nonthermal,
cellular-focused, CellFX System powered by NPS technology.”
Oral Presentation:
Emerging Technologies Abstract Session, Friday, April 29,
2022 at 2:00 PM - 3:30 PM PDT
Hot Topic: Long-term NPS Data for the Clearance of
Sebaceous Hyperplasia Shows High Levels of Clearance and Improved
Cosmesis When Using Low NPS Energy Settings
Presented by: Dr. Girish Munavalli, Charlotte, NC, on
Friday, April 29, 2022 at 2:27 PM - 2:32 PM PDT
Authors: Brenda LaTowsky, Scottsdale, AZ; Brian
Zelickson, Minneapolis, MN; Suzanne Kilmer, Sacramento, CA;
Elizabeth Tanzi, Chevy Chase, MD; Ava Shamban, Beverly Hills, CA;
Robert Weiss, Hunt Valley, MD; Darius R. Mehregan, Monroe, MI;
Lauren Johnston, Pulse Biosciences, Hayward, CA; and William Knape,
Pulse Biosciences, Hayward, CA
Poster
Title: Refractory Focal Epithelial Hyperplasia
Successfully Treated with Novel Use of Nano-Pulse Stimulation
Authors: May Elgash, MD; Julie Dhossche MD; Anna Bar,
MD
Pulse Biosciences also announced the debut of its first U.S.
exhibit at the ASLMS annual meeting. Attendees are encouraged to
visit Booth #721 to learn about the NPS mechanism, demo the CellFX
System and learn about real-world experiences from physicians and
their patients.
About NPS Presentations at the American Academy of
Dermatology
Pulse Biosciences is also pleased to recount its robust presence
at the recent 2022 American Academy of Dermatology Annual Meeting,
which was held on March 25-28, in Boston, MA. At the premier
gathering of renowned experts in dermatology, the science and
clinical applications of Nano-Pulse Stimulation technology were
featured in four educational sessions, including:
- What’s New and What’s True for Energy Based Devices In
Dermatology by Dr. Arisa Ortiz
- The Evolving Toolbox for Treating Difficult Warts by Dr. Peter
C. Friedman
- Therapeutic Hotline by Dr. Susan Weinkle
- Video Demonstration: Nano-Pulse Stimulation by Dr. Yakir
Levin
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that has the potential to improve
the quality of life for patients. The Company’s proprietary
Nano-Pulse Stimulation technology delivers nano-second pulses of
electrical energy to non-thermally clear cells while sparing
adjacent non-cellular tissue. The CellFX® System is the first
commercial product to harness the distinctive advantages of NPS
technology to treat a variety of applications for which an optimal
solution remains unfulfilled. The initial commercial use of the
CellFX System is to address a range of dermatologic conditions that
share high demand among patients and practitioners for improved
dermatologic outcomes. Designed as a multi-application platform,
the CellFX System offers customer value with a utilization-based
revenue model. Visit pulsebiosciences.com to learn more.
To stay informed about the CellFX System, please visit
CellFX.com and sign-up for updates.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220426005434/en/
Media: Tosk Communications Nadine D. Tosk 504.453.8344
nadinepr@gmail.com
Investors: Pulse Biosciences Sandra Gardiner, EVP and CFO
510.241.1077 IR@pulsebiosciences.com or Gilmartin Group Philip Trip
Taylor 415.937.5406 philip@gilmartinir.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Apr 2023 to Apr 2024